toxoplasma
gondii
oblig
intracellular
protozoan
belong
phylum
apicomplexa
parasit
heteroxen
life
cycl
differ
warm
blood
speci
includ
human
serv
intermedi
host
sustain
replic
asexu
form
tachyzoit
bradyzoit
domest
wild
felin
definit
host
develop
sexual
stage
parasit
gut
shed
infect
form
sporul
oocyst
fece
infect
type
host
may
occur
consumpt
meat
viscera
anim
infect
gondii
ingest
waterveget
contamin
sporul
oocyst
intermedi
definit
host
infect
follow
short
period
intens
replic
tachyzoit
culmin
ruptur
infect
cell
parasit
spread
initi
infect
site
tachyzoit
later
convert
slowrepl
bradyzoit
becom
enclos
intracellular
cyst
stage
convers
character
chronic
form
toxoplasmosi
persist
entir
life
host
host
immun
respons
play
major
role
control
tachyzoit
replic
stage
convers
hand
parasit
use
cyst
evad
complet
clearanc
immun
system
immunocompet
host
develop
strong
longlast
respons
product
well
activ
cell
essenti
surviv
infect
contribut
humor
immun
respons
control
toxoplasmosi
less
well
understood
studi
suggest
import
role
antibodi
acut
phase
infect
other
point
minor
influenc
immunoglobulin
parasit
control
chronic
diseas
healthi
adult
human
usual
develop
nonsymptomat
chronic
form
toxoplasmosi
howev
immunecompromis
individu
aid
patient
person
undergo
cancer
treatment
may
present
sever
form
diseas
enceph
pneumon
anoth
risk
group
consist
children
infect
pregnanc
depend
time
exposur
fetu
consequ
may
vari
abort
retinochoroid
mental
retard
intracrani
calcif
surviv
infant
approach
prevent
exposur
gondii
suffici
reduc
infect
occurr
toxoplasmosi
moreov
effect
treatment
chronic
form
diseas
avail
drug
like
sulfadiazin
act
prolif
tachyzoit
effect
encyst
bradyzoit
thu
develop
vaccin
gondii
import
altern
diseas
control
great
number
immun
strategi
test
gondii
includ
vaccin
base
attenu
parasit
protein
purifi
parasit
recombin
protein
dna
immunogen
confer
differ
level
protect
depend
type
antigen
deliveri
system
presenc
adjuv
vaccin
formul
vaccin
candid
limit
perspect
reach
use
human
contain
compon
potenti
hazard
live
parasit
adjuv
may
caus
inflammatori
side
effect
review
among
differ
approach
develop
immunogen
vaccin
protozoan
parasit
use
recombin
viral
vector
altern
great
potenti
viral
vector
typic
elicit
effici
express
foreign
antigen
encod
facilit
present
develop
specif
immun
respons
recombin
antigen
viral
vector
also
demonstr
activ
innat
immun
mechan
exert
adjuv
effect
improv
immun
respons
recombin
product
recombin
adenoviru
wellcharacter
viral
vector
use
express
antigen
number
infecti
agent
safe
test
variou
immun
protocol
wide
rang
host
includ
human
result
differ
degre
immun
respons
protect
one
limit
viral
vector
vaccin
approach
involv
recombin
antigen
fact
gener
protect
immun
respons
requir
multipl
exposur
immun
system
recombin
antigen
thu
viral
vector
adenoviru
normal
use
socal
prime
boost
vaccin
protocol
one
potenti
problem
sequenti
immun
type
viral
vector
homolog
prime
boost
primeimmun
vector
may
result
product
neutral
antibodi
could
interfer
transduct
cell
follow
round
immun
therefor
express
present
recombin
antigen
may
compromis
activ
immun
respons
attempt
circumv
vectorspecif
neutral
antibodi
increas
potenc
immun
mani
group
use
heterolog
vaccin
protocol
compris
differ
viral
vector
carri
antigen
modifi
vaccinia
viru
ankara
mva
obtain
serial
passag
vaccinia
viru
primari
chicken
embryo
fibroblast
result
viru
replicationdefici
highli
attenu
strain
histor
employ
safer
vaccin
altern
smallpox
time
high
safeti
profil
abil
induc
intens
express
foreign
gene
made
mva
prime
candid
vaccin
vector
moreov
demonstr
defect
morphogenet
program
render
mva
incap
replic
alter
express
recombin
antigen
mammalian
cell
compar
replicationcompet
vaccinia
viru
past
decad
group
engag
develop
vaccin
toxoplasmosi
base
recombin
adenovirus
encod
sequenc
surfac
antigen
gondii
three
conserv
abund
antigen
tachyzoit
surfac
believ
mediat
parasit
attach
host
cell
process
invas
individu
natur
infect
gondii
produc
antibodi
antigen
also
report
indic
antigen
epitop
present
context
differ
haplotyp
human
histocompat
complex
therefor
recogn
cell
believ
properti
make
sag
antigen
suitabl
candid
toxoplasmosi
vaccin
initi
three
virus
use
homolog
primeboost
protocol
provid
signific
level
protect
chronic
form
diseas
model
toxoplasmosi
balbc
challeng
pbr
strain
parasit
howev
differ
model
mice
challeng
strain
adenoviru
encod
antigen
show
protect
properti
observ
prompt
us
focu
investig
present
work
gener
mva
encod
antigen
use
heterolog
primeboost
protocol
combin
adenoviru
encod
antigen
aim
evalu
whether
combin
two
vector
could
result
improv
immun
respons
induc
higher
level
protect
experiment
toxoplasmosi
anim
hous
experiment
strictli
perform
accord
guidelin
set
forth
institut
ethic
committe
oswaldo
cruz
foundat
fiocruz
brazil
protocol
studi
registr
number
approv
institut
ethic
committe
fiocruz
six
eight
week
old
femal
swisswebst
mice
obtain
rene
rachou
research
center
fiocruz
belo
horizont
brazil
type
ii
strain
maintain
serial
passag
cyst
femal
swisswebst
mice
cyst
obtain
mous
brain
day
infect
use
challeng
vaccin
mice
rh
strain
maintain
serial
passag
periton
tachyzoit
employ
prepar
total
tachyzoit
lysat
antigen
tla
previous
describ
tissu
cultur
medium
ack
red
cell
lyse
antirabbit
total
igg
antimous
total
igg
antimous
substrat
use
elisa
elispot
develop
obtain
sigma
mo
usa
antimous
purchas
southern
biotech
al
usa
chemiluminesc
reagent
autoradiographi
film
use
western
blot
develop
purchas
amershang
health
care
nj
usa
fetal
bovin
serum
fb
obtain
gibco
ca
usa
antibodi
streptoavidinperoxidas
conjug
use
elispot
well
brefeldin
antibodi
use
intracellular
stain
obtain
bd
bioscienc
ca
usa
antibodi
use
cell
surfac
marker
intracellular
stain
purchas
ebiosci
ca
usa
elisa
kit
use
detect
cytokin
secret
spleen
cell
purchas
r
system
inc
mn
usa
mhcibind
peptid
deriv
use
cell
stimul
synthes
depart
immunolog
feder
univers
mina
gerai
mg
brazil
rabbit
antit
gondii
serum
use
detect
westernblot
produc
depart
parasitolog
feder
univers
mina
gerai
recombin
mva
encod
antigen
obtain
homolog
recombin
transfer
vector
genom
wild
type
mva
plasmid
green
fluoresc
protein
gfp
report
gene
control
promot
vaccinia
viru
late
promot
express
cassett
control
artifici
promot
allow
constitut
express
heterolog
gene
recombin
cassett
contain
recombin
antigen
gfp
report
insert
genom
mva
gener
recombin
viru
construct
carri
heterolog
gene
transfect
chicken
embryo
fibroblast
cef
previous
infect
one
hour
earlier
wild
type
mva
multipl
infect
viral
particl
per
cell
infectedtransfect
cef
cultur
incub
three
day
presenc
recombin
virus
cef
cultur
confirm
express
green
fluoresc
spot
monolay
could
detect
epifluoresc
microscop
supernat
cell
lysat
obtain
origin
gfp
posit
cultur
use
reinfect
fresh
cef
monolay
expans
viral
seed
round
expans
viral
seed
submit
plaqu
purif
ensur
elimin
wild
type
mva
purpos
origin
viral
stock
submit
limit
dilut
use
infect
cef
cultur
cultur
present
singl
fluoresc
plaqu
collect
dilut
use
infect
fresh
cef
process
limit
dilut
infect
select
cultur
contain
singl
viral
plaqu
repeat
seven
consecut
time
singl
plaqu
obtain
seventh
round
purif
consid
clone
expand
purif
test
express
purif
virus
perform
centrifug
sucros
cushion
wv
recombin
virus
identifi
detect
gfpexpress
infect
cell
flow
cytometri
express
evalu
western
blot
assay
mice
receiv
recombin
adenoviru
express
alon
homolog
protocol
altern
combin
mva
express
antigen
heterolog
protocol
vaccin
control
anim
receiv
adenoviru
encod
e
coli
adctrl
alon
combin
mva
encod
gfp
report
mvactrl
homolog
vaccin
protocol
anim
receiv
two
subcutan
dose
plaqueform
unit
pfu
adenovirus
week
interv
dose
heterolog
protocol
anim
receiv
one
subcutan
prime
dose
pfu
adenoviru
follow
week
later
intramuscular
dose
pfu
serum
spleen
sampl
obtain
day
last
dose
viru
surviv
experi
mice
oral
challeng
cyst
strain
day
last
vaccin
mortal
follow
day
survivor
sacrif
end
period
quantif
cyst
brain
spleen
collect
day
last
vaccin
disrupt
cell
strainer
obtain
singl
cell
suspens
red
blood
cell
lyse
buffer
remain
spleen
cell
submit
two
wash
complet
medium
rpmi
supplement
fb
total
spleen
cell
plate
plain
complet
medium
presenc
total
tachyzoit
lysat
antigen
tla
mhcibind
synthet
peptid
deriv
cell
cultur
hour
stimul
cell
cultur
supernat
use
detect
cytokin
produc
cell
elispot
assay
spleen
cell
cultur
stimuli
hour
nitrocellulosebottom
microtit
plate
previous
coat
antimous
monoclon
antibodi
clone
mgml
block
complet
medium
cell
stimul
plate
wash
thoroughli
incub
biotinyl
antimous
antibodi
clone
mgml
follow
peroxidaselabel
streptoavidin
spot
develop
tetrahydrochlorid
substrat
reaction
stop
run
water
number
spot
determin
ctlimmunospot
counter
cellular
technolog
ltd
oh
usa
intracellular
cytokin
detect
total
spleen
cell
cultur
hour
stimuli
brefeldin
ad
cultur
last
hour
incub
cell
wash
twice
assay
buffer
pb
supplement
bovin
serum
albumin
prior
stain
cell
treat
receptor
blocker
purifi
antimous
clone
assay
buffer
minut
ice
cell
submit
surfac
stain
conjug
clone
conjug
clone
dilut
assay
buffer
minut
ice
cell
wash
twice
assay
buffer
fix
formaldehyd
minut
room
temperatur
next
cell
permeabil
pb
supplement
tween
ice
minut
final
cell
stain
antibodi
intracellular
pe
conjug
clone
conjug
clone
minut
ice
cell
wash
twice
suspend
assay
buffer
event
acquir
bd
lsrii
cytomet
analyz
flowjo
three
strar
inc
usa
detect
secret
cytokin
total
spleen
cell
cultur
stimuli
hour
cellfre
cultur
supernat
test
use
commerci
cytokin
elisa
kit
orient
manufactur
briefli
microtit
plate
coat
overnight
captur
antibodi
dilut
pb
block
pb
contain
bovin
serum
albumin
assay
diluent
hour
supernat
spleen
cell
cultur
vaccin
mice
standard
ad
plate
hour
wash
plate
pb
supplement
tween
wash
buffer
secondari
antibodi
ad
plate
hour
detect
reagent
streptavidinhrp
conjug
dilut
assay
diluent
ad
previous
wash
plate
minut
reaction
develop
peroxidas
substrat
contain
tetramethylbenzidin
stop
read
nm
character
express
mvactrlinfect
cell
lysat
run
polyacrylamid
gel
denatur
condit
transfer
onto
nitrocellulos
membran
sequenc
membran
block
pb
supplement
skim
milk
incub
antit
gondii
rabbit
serum
wash
thoroughli
incub
peroxidaseconjug
goat
antirabbit
total
igg
detect
igg
mous
serum
tla
run
transfer
condit
sequenc
tlaload
membran
strip
block
incub
individu
sampl
vaccin
control
mice
serum
wash
thoroughli
incub
peroxidaseconjug
antimous
total
igg
westernblot
reaction
develop
chemiluminesc
substrat
detect
exposur
membran
autoradiographi
film
elisa
assay
microtit
plate
previous
coat
overnight
tla
block
h
pb
supplement
fb
dilut
serum
sampl
ad
h
detect
antibodi
perform
peroxidaseconjug
goat
antimous
min
incub
plate
wash
time
pb
contain
tween
reaction
develop
peroxidas
substrat
contain
tetramethylbenzidin
stop
read
nm
mortal
curv
differ
immun
group
infect
strain
compar
use
chisquar
test
compar
number
brain
cyst
use
test
mannwhitney
compar
igg
titer
serum
use
pair
test
compar
number
spot
percentag
cytokin
secret
cell
level
secret
cytokin
use
twoway
anova
bonferroni
posttest
multipl
comparison
test
perform
graphpad
prism
version
graphpad
softwar
inc
la
jolla
usa
differ
consid
statist
signific
p
recombin
gener
homolog
intracellular
recombin
plasmid
encod
gene
genom
wild
type
mva
sequenc
gene
excis
plasmid
use
bglii
hindiii
endonucleas
stagger
end
fill
dna
polymeras
bluntend
fragment
insert
smai
site
plasmid
figur
left
construct
contain
correct
orient
figur
right
transfect
cef
previous
infect
wild
type
mva
posit
recombin
mva
well
gener
new
virus
confirm
express
gfp
report
infectedtransfect
cell
figur
left
newli
obtain
recombin
virus
submit
seven
round
select
elimin
contamin
wild
type
viru
express
protein
recombin
virus
confirm
western
blot
assay
extract
infect
cef
show
figur
right
order
veriti
immun
vector
encod
antigen
induc
adequ
vivo
express
protein
evalu
presenc
specif
antibodi
mous
serum
sampl
vaccin
mice
immun
accord
homolog
protocol
consist
two
dose
adenoviru
altern
submit
heterolog
protocol
one
prime
dose
adenoviru
follow
one
dose
mva
tabl
two
week
last
viral
dose
serum
sampl
test
western
blot
use
total
tachyzoit
lysat
tla
antigen
figur
show
sera
mice
react
one
band
around
kd
correspond
serum
sampl
also
test
elisa
assay
show
presenc
differ
class
igg
antibodi
name
vaccin
mice
level
igg
subclass
compar
two
vaccin
protocol
known
product
igg
subclass
driven
cytokin
secret
cellular
immun
respons
therefor
presenc
suggest
indirectli
vaccin
protocol
also
promot
activ
cellmedi
respons
two
week
last
viral
dose
splenocyt
obtain
immun
mice
submit
stimul
gondii
antigen
evalu
frequenc
cell
produc
describ
method
section
figur
figur
show
upon
stimul
tla
spleen
anim
receiv
virus
encod
present
higher
frequenc
cell
produc
figur
figur
comparison
controlvaccin
mice
observ
heterologousvaccin
mice
tend
develop
higher
frequenc
tlarespond
cell
although
case
produc
lymphocyt
differ
protocol
reach
level
statist
signific
discret
increas
number
produc
lymphocyt
reflect
modest
signific
increment
level
secret
supernat
spleen
cell
cultur
heterologousvaccin
anim
figur
amount
cell
supernat
detect
level
assay
group
analysi
specif
cell
popul
elicit
vaccin
yield
similar
find
figur
figur
heterologousvaccin
tend
develop
higher
number
figur
figur
produc
cell
respons
stimul
mhcirestrict
peptid
elispot
assay
figur
left
confirm
increas
frequenc
secret
specif
cell
heterologousvaccin
spleen
reflect
higher
level
secret
spleen
cultur
group
figur
right
evalu
protect
confer
vaccin
protocol
challeng
mice
strain
gondii
observ
model
recombin
vaccin
show
protect
achiev
multipl
dose
recombin
immunogen
administr
singl
dose
either
prevent
mortal
figur
case
mice
immun
two
viral
dose
verifi
tendenc
higher
surviv
anim
heterolog
protocol
compar
homolog
protocol
figur
also
evalu
number
cyst
brain
surviv
anim
shown
figur
observ
mice
heterolog
vaccin
group
develop
significantli
lower
p
number
brain
cyst
comparison
anim
homolog
vaccin
group
recombin
vaccin
great
potenti
futur
util
prevent
therapi
diseas
caus
intracellular
parasit
includ
gondii
success
recombin
vaccin
depend
mani
factor
includ
identif
select
parasit
compon
target
host
immun
system
design
power
vector
induc
effici
vivo
express
antigen
anoth
key
point
character
innat
immun
mechan
adjuv
regul
activ
acquir
immun
respons
develop
memori
vaccin
final
equal
import
develop
vaccin
protocol
ensur
host
immun
system
expos
antigen
adjuv
adequ
amount
right
length
time
strategi
develop
antitoxoplasmosi
recombin
vaccin
gener
viral
vector
express
gondii
antigen
work
center
surfac
protein
express
tachyzoit
mediat
adhes
parasit
surfac
host
cell
prior
invas
epitop
recogn
mice
experiment
inocul
gondii
human
natur
infect
parasit
characterist
make
promis
candid
develop
vaccin
fact
studi
group
administ
mice
differ
form
protocol
abl
protect
varieti
gondii
strain
regard
vaccin
vector
use
express
start
work
replicationdefici
type
human
adenoviru
besid
highli
effici
transgen
express
vivo
safe
administr
adenovir
vector
also
intrins
adjuv
properti
capabl
activ
innat
immun
respons
via
tlr
nlr
receptor
consequ
adenovir
vector
excel
induc
cellular
respons
activ
cell
capabl
produc
type
acquir
respons
essenti
protect
gondii
use
homolog
protocol
obtain
partial
protect
cyst
format
model
chronic
toxoplasmosi
caus
pbr
strain
balbc
mice
vaccin
abl
reduc
acut
mortal
reduc
cyst
format
mice
challeng
strain
protect
correl
capac
activ
cellmedi
respons
mechan
depend
innat
signal
product
address
improv
vaccin
strategi
enhanc
level
protect
sens
one
major
limit
viral
vector
vaccin
exist
antivector
immun
reduc
effici
immun
antivector
immun
induc
natur
exposit
host
wild
type
virus
use
base
construct
vector
besid
antivector
block
respons
induc
cours
vaccin
recombin
virus
one
import
antivir
mechan
product
neutral
antibodi
prevent
effici
transduct
host
cell
recombin
virus
consequ
impair
antigen
express
present
vivo
moreov
immun
respons
viral
epitop
trigger
quick
elimin
transduc
cell
could
result
weak
immunogen
low
protect
profil
adenovirusbas
vaccin
protocol
demonstr
transfer
serum
anim
previous
expos
adenoviru
nonimmun
mice
limit
target
gene
express
transfer
cell
limit
immun
respons
gene
carri
viral
vector
also
preexist
antiadenoviru
specif
cell
account
decreas
cellular
immun
respons
observ
antihiv
vaccin
trial
conduct
human
use
adenoviru
vaccin
vector
observ
suggest
level
preexist
immun
adenoviru
may
one
underli
caus
variat
efficaci
differ
vaccin
model
use
virus
strategi
employ
avert
antiadenoviru
immun
includ
use
rare
human
serotyp
nonhuman
serotyp
develop
vaccin
vector
approach
introduct
modif
surfac
antigen
use
polym
abl
mask
viral
surfac
neutral
antibodi
although
methodolog
may
reduc
effect
preexist
antibodi
gener
natur
exposit
host
wild
type
virus
prevent
induct
antivector
immun
vaccin
case
approach
avoid
antivector
immun
combin
variou
vector
carri
antigen
socal
heterolog
protocol
last
year
mva
becom
popular
recombin
viral
vector
develop
immun
protocol
vector
capabl
activ
humor
cellular
immun
respons
heterolog
gene
also
differ
studi
prove
mva
safe
vector
human
anim
mva
frequent
indic
vector
choic
reinforc
initi
immun
respons
gener
prime
dna
adenovirus
take
previou
observ
consider
chose
gener
recombin
mva
encod
antigen
gondii
use
adenovirus
primeboost
immun
protocol
vector
capabl
induc
high
level
express
recombin
protein
vitro
show
stabil
sever
passag
cef
data
shown
compar
homolog
vaccin
protocol
two
dose
heterolog
protocol
one
dose
follow
observ
protocol
abl
induc
protect
challeng
although
protect
mortal
compar
protocol
heterolog
vaccin
promot
signific
reduct
parasit
burden
brain
compar
homolog
immun
differ
seem
relat
vaccineinduc
humor
respons
group
develop
similar
level
antibodi
observ
consist
anoth
studi
show
b
celldefici
mice
vaccin
attenu
strain
gondii
abl
control
parasit
burden
oral
challeng
effici
wild
type
mice
hand
well
establish
protect
cyst
format
primarili
depend
strong
cellmedi
immun
nevertheless
analysi
cell
respons
show
modest
differ
two
protocol
least
term
frequenc
cell
produc
indic
import
aspect
cell
function
evalu
may
differenti
activ
vaccin
protocol
may
account
differ
protect
cyst
one
aspect
polyfunction
cell
capac
produc
multipl
cytokin
time
sever
vaccin
studi
correl
polyfunction
improv
protect
infecti
challeng
reyessandov
cowork
exampl
demonstr
mice
model
p
berghei
adenovirusmva
heterolog
vaccin
protocol
result
activ
polyfunct
cell
produc
observ
homolog
vaccin
report
suggest
thorough
evalu
efficaci
vaccin
protocol
involv
measur
potenc
respons
also
qualiti
although
abl
evalu
induct
polyfunct
cell
model
specul
may
induc
effici
adenovirusmva
vaccin
result
enhanc
capac
control
load
brain
cyst
group
anoth
import
aspect
cell
function
elimin
parasit
infect
cell
cytotox
lymphocyt
studi
shown
ctl
involv
cyst
control
gondii
infect
mechan
mediat
perforin
attempt
develop
vivo
cytotox
assay
mice
inocul
target
cell
coat
epitop
tptenhftl
initi
assay
howev
fail
detect
ctl
activ
homolog
heterolog
protocol
data
shown
investig
necessari
determin
statu
ctl
activ
vaccin
model
final
one
advantag
heterolog
protocol
demonstr
vaccin
model
enhanc
capabl
induc
longlast
cell
memori
although
investig
memori
cell
respons
studi
data
show
better
control
develop
brain
cyst
heterolog
vaccin
mice
chronic
phase
toxoplasmosi
depend
longlast
cell
indic
superior
memori
induct
heterolog
protocol
summari
result
suggest
combin
adenovirusmva
vector
express
capabl
improv
protect
cyst
format
chronic
toxoplasmosi
comparison
homolog
protocol
use
two
dose
adenovirus
encod
antigen
gondii
enhanc
protect
relat
increas
magnitud
cell
respons
real
mechan
behind
improv
cyst
control
need
investig
